EATG » Scientific research

Scientific research

EUPATI webinar: Presentations now available online

On 30 January 2017 EUPATI held a webinar focused on the revision of the ethical guidelines for biomedical research of the Council for International Organizations of Medical Sciences (CIOMS). David…

New nano approach could cut dose of leading HIV treatment in half

Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI)…

HIV attack on brain cells points to new dementia treatments

Scientists have discovered that a protein closely involved in AIDS-related dementia could provide clues for treating other forms of dementia. A team of MRC-funded scientists from Cardiff University and researchers…

HIV hijacks common cells to spread infection

Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF), together with collaborators in Europe, discovered that a common type of cell within the human reproductive and…

News from CROI2017? Here is your coverage

If you want to follow the news from the Conference on Retroviruses and Opportunistic Infections CROI currently held in Seattle, USA, we recommend the following online reporting sources. EATG, as…

Nanotechnology based gene editing to eradicate HIV brain reservoir in drug abusers

Opiate abuse is a significant risk factor for HIV infection, and in combination they can have a devastating effect on the brain. Scientists at FIU Herbert Wertheim College of Medicine…

NIH research helps explain how antibody treatment led to sustained remission of HIV-like virus

Scientists at the National Institutes of Health have found that the presence of the protein alpha-4 beta-7 integrin on the surface of HIV and its monkey equivalent — simian immunodeficiency…

Gilead announces findings from new preclinical study evaluating novel class of HIV capsid inhibitors

– Findings support continued investigation of inhibitor class as part of a long-acting antiretroviral HIV treatment strategy – SEATTLE, Feb. 13, 2017-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced findings from…

Seattle-lite: pre-conference workshops – watch online

The commitment to providing all presentations online as open access educational resources is one of the most impressive aspect of the annual CROI meetings. Options include to watch the presentations…

Collaboration on novel cellular therapies for long term HIV control

Bioquark Inc. and SC21 Biotech are collaborating on novel cellular therapies for long term HIV control by cost effectively and industrially scaling the production of HIV resistant cells for allogeneic…